Roche (VTX:ROG) has been given a CHF 260 target price by analysts at Berenberg Bank in a research note issued to investors on Monday, November 20th. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Berenberg Bank’s target price indicates a potential upside of 5.18% from the stock’s previous close.
Other analysts also recently issued research reports about the stock. Morgan Stanley set a CHF 260 target price on shares of Roche and gave the company a “neutral” rating in a report on Wednesday, July 26th. Credit Suisse Group set a CHF 260 target price on shares of Roche and gave the stock a “neutral” rating in a research note on Monday, October 16th. Baader Bank set a CHF 231 target price on shares of Roche and gave the stock a “neutral” rating in a research note on Thursday, October 19th. Kepler Capital Markets set a CHF 230 target price on shares of Roche and gave the stock a “neutral” rating in a research note on Monday, September 11th. Finally, Goldman Sachs Group set a CHF 325 price target on shares of Roche and gave the company a “buy” rating in a research report on Monday, September 11th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of CHF 261.32.
Roche (VTX ROG) traded up CHF 2.10 during mid-day trading on Monday, hitting CHF 247.20. 1,700,000 shares of the stock traded hands, compared to its average volume of 1,720,000. Roche has a 1 year low of CHF 219.10 and a 1 year high of CHF 273.
TRADEMARK VIOLATION NOTICE: “Roche (ROG) Given a CHF 260 Price Target at Berenberg Bank” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/roche-holding-ltd-rog-given-a-chf-260-price-target-by-berenberg-bank-analysts.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.